| CAS NO: | 1445879-21-9 |
| 包装 | 价格(元) |
| 5mg | 电议 |
| 10mg | 电议 |
| 25mg | 电议 |
| 50mg | 电议 |
| Physical Appearance | A crystalline solid |
| Storage | Store at -20°C |
| M.Wt | 649.62 |
| Cas No. | 1445879-21-9 |
| Formula | C31H25F2N5O7S |
| Solubility | ≥9.12 mg/mL in DMSO with ultrasonic; insoluble in EtOH; insoluble in H2O |
| Chemical Name | 3-((3-(N-cyclopropylsulfamoyl)-7-(2,4-dimethoxypyrimidin-5-yl)quinolin-4-yl)amino)-5-(3,5-difluorophenoxy)benzoic acid |
| Canonical SMILES | O=S(C(C=N1)=C(NC2=CC(OC3=CC(F)=CC(F)=C3)=CC(C(O)=O)=C2)C(C1=C4)=CC=C4C5=CN=C(OC)N=C5OC)(NC6CC6)=O |
| 运输条件 | 蓝冰运输或根据您的需求运输。 |
| 一般建议 | 为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异，仅做参考。若实验所需浓度过大至产品溶解极限，请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存，请尽快用完。 |
GSK2837808A is a potent, selective lactate dehydrogenase A (LDHA) inhibitor (IC50 values are 1.9 and 14 nM for LDHA and LDHB respectively).
In Snu398 but not HepG2 hepatocellular carcinoma cells. GSK2837808A (10 μM) reduces glucose consumption.
After intravenous injection of GSK2837808A at 0.25 mg/kg in rats, the clearance is shown to be 69 mL/min/kg, which exceeds the blood flow of the animal liver. Oral administration of GSK2837808A at 50 mg/kg or 100 mg/kg in rats or mice, respectively, resulted in blood compound levels reaching or below the detection limit of 2.5 ng/mL.
Reference:
[1]. Billiard J, Dennison J B, Briand J, et al. Quinoline 3-sulfonamides inhibit lactate dehydrogenase A and reverse aerobic glycolysis in cancer cells. Cancer & Metabolism, 2013, 1(1): 19-19.
m.cnreagent.com